Drug Profile


Alternative Names: Denufosol tetrasodium; INS 37217; INS 37217 ophthalmic; INS37217 Respiratory

Latest Information Update: 18 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inspire Pharmaceuticals
  • Class Decongestants; Expectorants; Eye disorder therapies; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Purinoceptor P2U agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis

Highest Development Phases

  • Discontinued Cystic fibrosis; Dry eyes; Perennial allergic rhinitis; Retinal disorders; Retinal oedema; Sinusitis

Most Recent Events

  • 18 Feb 2011 Discontinued - Phase-II for Cystic fibrosis in USA (Inhalation)
  • 18 Feb 2011 Discontinued - Phase-III for Cystic fibrosis in Australia (Inhalation)
  • 18 Feb 2011 Discontinued - Phase-III for Cystic fibrosis in Canada (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top